CARDIFF UNIVERSITY
PRIFYSGOL CAERDYDD

ORCA – Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/106078/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Culshaw, Abigail, Ladell, Kristin , Gras, Stephanie, McLaren, James E. , Miners, Kelly L., Farenc, Carine, van den Heuvel, Heleen, Gostick, Emma, Dejnirattisai, Wanwisa, Wangteeraprasert, Apirath, Duangchinda, Thaneeya, Chotiyarnwong, Pojchong, Limpitikul, Wannee, Vasanawathana, Sirijitt, Malasit, Prida, Dong, Tao, Rossjohn, Jamie , Mongkolsapaya, Juthathip, Price, David A. and Screaton, Gavin R. 2017. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. Nature Immunology 18 , pp. 1228-1237. 10.1038/ni.3850

Publishers page: http://dx.doi.org/10.1038/ni.3850

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.

	Sample ID	Day[a]	Previous infection[b]	Recent infection[c]	DF/DHF	% GTS[d]					
						1	2	3/4	1&2	1&3/4	2&3/4
Primary cases	1-1166-6	8	N/A	DENV1	DHFII	0.161					
	1-2368-2	15	N/A	DENV1	DF	0.652					
	1-2528-9	8	N/A	DENV1	DF	0.097					
	2-0600-8	15	N/A	DENV1	DF	0.242					
	2-2781-2	17	N/A	DENV1	DF	1.05					
Secondary cases	2-1452-5	12	DENV1	DENV2	DHFI	0.258	0.054		0.045		
	2-1629-2	16	DENV1	DENV4	DF	0.358		0.346		0.685	
	2-1630-3	16	DENV1	DENV4	DF	0.079		0.185		0.435	
	2-0573-8	14	DENV1	DENV4	DF	0.57		0.426		4.56	
	2-1710-2	15	DENV3	DENV1	DHFII	0.072		0.055		0.219	
	2-0664-9	12	DENV3	DENV1	DHFII	0.497		0.258		0.942	
	2-1680-8	9	DENV2	DENV4	DF		0.546	0.083			0.119
	2-0885-5	12	DENV3	DENV2	DHFII		0.898	0.838			1.15
	2-1672-9	18	DENV4	DENV2	DF		0.575	2.09			0.6

Supplementary Table 1 Patient samples used to determine the TCRβ repertoire of $CD8^+$ HLA-A*11:01p $tetramer^+$ cells. [a]Day post-defervescence. [b]Previous infection determined by micro-FRNTs. [c]Recent infection determined by RT-PCR. [d]Frequency (%) of $CD8^+$ HLA-A*11:01p $tetramer^+$ cells. DF, dengue fever; DHF, dengue haemorrhagic fever.

TRBV	CDR3	TRBJ	Sample	Infection history	Sorted population	Freq. (%)
12-3/4	CASSLGAGELF	2-2	1-1166	Primary DENV1	1 SP	1.41
			2-1710	Secondary DENV3/DENV1	1&3/4 DP	1.82
11-2	CASSLGPDNEQF	2-1	2-2781	Primary DENV1	1 SP	10.45
			2-6449	Secondary DENV3/DENV1	1&3/4 DP	1.37
11-2	CASSLGQGAYEQY	2-7	2-2781	Primary DENV1	1 SP	2.99
			2-1629	Secondary DENV1/DENV4	1&3/4 DP	20.73
11-2	CASSLGGTDNEQF	2-1	2-1629	Secondary DENV1/DENV4	1&3/4 DP	14.63
			2-6449	Secondary DENV3/DENV1	1&3/4 DP	1.37
11-2	CASSLGPDYEQY	2-7	2-1629	Secondary DENV1/DENV4	3/4 SP, 1&3/4 DP	2.63, 2.44
			2-0573	Secondary DENV1/DENV4	3/3 SP	2.17
11-2	CASSLGGDTYEQY	2-7	2-1629	Secondary DENV1/DENV4	1&3/4 DP	13.41
			2-6449	Secondary DENV3/DENV1	1&3/4 DP	4.11
11-2	CASSLGPDSPLH	1-6	2-1672	Secondary DENV4/DENV2	3/4 SP	3.17
			2-6649	Secondary DENV3/DENV1	1&3/4 DP	1.37
6-5	CASSYRGGRAGETQY	2-5	2-0885	Secondary DENV3/DENV2	2&3/4 DP	2.5
			2-1710	Secondary DENV3/DENV1	1&3/4 DP	3.64

Supplementary Table 2 Public $NS3_{133}$ DENV-specific TCRβ sequences isolated from patients with primary or secondary DENV infection. SP, single positive; DP, double positive.

Lab no.	Day[a]	Previous infection[b]	Recent infection[c]	DF/DHF	% GTS[d]	% TRBV11-2[e]
02-0095	15	ND	DV1	DHF II	3.45	35.07
02-0608-7	12	INC	DV1	DF	0.383	6.27
02-0835-9	12	INC	DV1	DF	1.344	26.79
02-0921-5	15	INC	DV1	DF	0.92	25.98
02-1034-1	20	INC	DV1	DF	0.886	23.7
02-1092-5	13	INC	DV1	DHF II	0.211	19.43
02-1180-3	18	INC	DV1	DHF II	1.63	43.31
03-0598	23	ND	DV1	DHF II	10.53	26.12
03-0685	18	ND	DV1	DHF I	1.664	24.82
03-0686	18	ND	DV1	DHF II	0.243	32.51
03-0681	18	ND	DV4	DF	1.306	47.63
01-0019-2	23	ND	DV2	DHF I	0.17	5.29
02-0192	14	ND	DV2	DHF III	0.438	1.37
02-0285	21	ND	DV2	DHF I	0.254	3.54
02-1628-1	17	INC	DV2	DF	0.112	14.29
02-1652-7	16	INC	DV2	DF	0.922	34.16
03-0007	18	ND	DV2	DHF I	0.14	5
03-0214	16	ND	DV2	DHF I	2.259	74.81
03-0252	20	ND	DV2	DHF III	0.923	3.36
03-0407	24	ND	DV2	DHF I	0.131	5.34
03-0488	15	ND	DV2	DHF I	0.207	35.75
03-0524	23	ND	DV2	DHF III	0.156	6.41
03-0614	33	ND	DV2	DHF III	0.182	16.48

Supplementary Table 3 Patient samples used to determine the frequency (%) of $CD8^+$ HLA-A*11:01p $tetramer^+$ cells expressing TRBV11-2 (Fig. 1a,b). [a]Day post-defervescence. [b]Previous infection determined by micro-FRNTs. [c]Recent infection determined by RT-PCR. [d]Frequency (%) of $CD8^+$ HLA-A*11:01p $tetramer^+$ cells. [e]Frequency (%) of $CD8^+$ HLA-A*11:01p $tetramer^+$ cells expressing TRBV11-2. DF, dengue fever; DHF, dengue haemorrhagic fever; INC, inconclusive; ND, not determined.

TCR	D30	HLA-A*11:01	HLA-A*11:01	Bond type
CDR1α	Ala28-O	Arg163-NH2	Arg163	VDW, HB
CDR1α	Leu29	-	Arg163	VDW
CDR1α	Tyr30-OH	Arg163	Arg163-Nε	VDW, HB
CDR2α	Lys58	Ala158	-	VDW
CDR3α	Asp109-Oδ1-Oδ2	Gln62-Nε2-Oε1 Arg65-NH1	Gln62-Oε1-Nε2 Arg65-NH1	VDW, HB, SB
CDR3α	Ala110	Gln62, Asn66	Gln62, Asn66	VDW
CDR3α	Gly111	-	Asn66	VDW
CDR3α	Met113	Arg65	Arg65	VDW
CDR2β	Gln57-Nε2	Ala69, Gln72 Thr73-Oγ1	Ala69, Gln72, Thr73-Oγ1	VDW, HB
CDR2β	Asn58-Oδ1	Val76, Gln72-O Thr73	Val76, Gln72, Thr73	VDW, HB
CDR2β	Asn59	Gln72	Val76	VDW
CDR2β	Gly60-N	Gln72-Oε1	Gln72-Oε1	VDW, HB
CDR2β	Val61	-	Lys68	VDW
FWβ	Val66	Arg65, Lys68, Ala69	Arg65, Lys68, Ala69	VDW
FWβ	Asp67-Oδ2	Arg65-Nε	Arg65-Nε	VDW, SB
CDR3β	Leu108	Ala150	Ala150	VDW
CDR3β	Gln110	Ala69	Ala69	VDW
CDR3β	Gly111-O	Gln155-Nε2	Gln155	VDW, HB
CDR3β	Leu112-O	Gln155-Nε2	Gln155	VDW, HB
CDR3β	Leu113	Glu154, Gln155	Gln155, His151	VDW
CDR3β	Tyr114-OH	Ala150-O, Gln155-Oε1	Ala150-O, Gln155-Oε1	VDW, HB

VDW, van der Waals (cut-off, 4Å); HB, hydrogen bond (cut-off, 3.5Å); SB, salt bridge (cut-off, 5Å).

TCR	D30	GTS1	GTS3/4	Bond type
CDR3α	Ala110-O	Gly4, Ser5-N	Gly4, Ser5-N	VDW, HB
CDR3α	Gly111	Gly4	Gly4	VDW
CDR1β	Ala30	Asn9	Asn9	VDW
CDR2β	Gln57-Oε1	Ile7-O	Ile7-O	VDW, HB
CDR2β	Asn58-Oδ1-Nδ2	Asn9-Nδ2-Oδ1	Asn9-Nδ2-Oδ1	VDW, HB
CDR3β	Gly109	Val8	Ile7, Val8	VDW
CDR3β	Gln110-Oε1-O	Gly4-O, Ser5, Pro6 Ile7-O-N	Gly4-O, Ser5, Pro6, Ile7-O	VDW, HB
CDR3β	Gly111-O	Ser5-Oγ	Ser5	VDW, HB
CDR3β	Leu112	Ser5	Ser5	VDW
CDR3β	Tyr114	Val8	Ile8	VDW

VDW, van der Waals (cut-off, 4Å); HB, hydrogen bond (cut-off, 3.5Å); SB, salt bridge (cut-off, 5Å).

Supplementary Table 4 Contacts between the D30 TCR and HLA-A*11:01 presenting GTS1 or GTS3/4.

TCR segment	D30 TCRβ mutants	K_{Deq} (μM)	Impact
	WT	136.0 ± 7.0	
CDR1β	G28A	251.9 ± 6.7	∗
CDR1β	A30G	190.0 ± 18.9	∗
CDR2β	Q57A	NB	∗∗∗
CDR2β	N58A	>> 400	∗∗∗
CDR2β	N59A	28.51 ± 1.2	#
FWβ (control)	L81A	103.3 ± 8.3	∗
CDR3β	L108A	NB	∗∗∗
CDR3β	G109A	NB	∗∗∗
CDR3β	Q110A	>> 400	∗∗∗
CDR3β	G111A	>> 400	∗∗∗
CDR3β	L112A	>> 400	∗∗∗
CDR3β	L113A	158.5 ± 8.9	∗

Supplementary Table 5 Equilibrium binding affinities of soluble HLA-A*11:01-GTS1 complexes for wild-type and mutant D30 TCRs. NB, no binding at 400 μM HLA-A*11:01-GTS1; WT, wild-type; ∗, minimal impact (< 3-fold change in affinity); ∗∗∗, critical impact (> 5-fold decrease in affinity); #, positive impact (> 3-fold increase in affinity).

HLA-A*11:01	D2H TCR	Impact	D13 TCR	Impact	D30 TCR	Impact
WT	7.3 ± 0.9		> 400		136.0 ± 7.0	
R65A	15.8 ± 1.1	∗	NB	∗∗∗	NB	∗∗∗
K68A	29.3 ± 1.4	∗∗	NB	∗∗∗	> 400	∗∗
Q72A	6.3 ± 0.6	∗	106.8 ± 2.0	#	23.5 ± 0.8	#
V76A	41.4 ± 3.0	∗∗∗	> 400	∗	106.3 ± 2.9	∗
R145A (control)	10.1 ± 0.8	∗	> 400	∗	186.4 ± 4.1	∗
E154A	10.5 ± 0.8	∗	> 400	∗	186.7 ± 4.3	∗
Q155A	82.4 ± 7.8	∗∗∗	> 400	∗	>> 400	∗∗∗

NB, no binding at 400 μM HLA-A*11:01-GTS1; WT, wild-type; ∗, minimal impact (< 3-fold change in affinity); ∗∗, moderate impact (3–5-fold decrease in affinity); ∗∗∗, critical impact (> 5-fold decrease in affinity); #, positive impact (> 3-fold increase in affinity). Numbers indicate K_{Deq} values (μM).!

GTS1	D2H TCR	Impact	D13 TCR	Impact	D30 TCR	Impact
S5A	12.7 ± 1.3	∗	289.6 ± 4.6	∗	>> 400	∗∗∗
N9D	216.4 ± 24.2	∗∗∗	NB	∗∗∗	>> 400	∗∗∗
N9A	79.4 ± 10.8	∗∗∗	>> 400	∗∗∗	375.8 ± 7.6	∗∗

NB, no binding at 400 μM HLA-A*11:01-GTS1; ∗, minimal impact (< 3-fold change in affinity); ∗∗, moderate impact (3–5-fold decrease in affinity); ∗∗∗, critical impact (> 5-fold decrease in affinity). Numbers indicate K_{Deq} values (μM).

Supplementary Table 6 Equilibrium binding affinities of soluble wild-type and mutant HLA-A*11:01-GTS1 complexes for the D2H, D13, and D30 TCRs.

GTS1	T_M (°C)
GTSGSPIVNR (GTS1)	61.6 ± 0.8
GTSG**A**PIVNR (GTS1-A5)	61.7 ± 1.0
GTSGSPIV**A**R (GTS1-A9)	55.8 ± 1.3
GTSGSPIV**D**R (GTS1-D9)	60.5 ± 1.0

HLA-A*11:01	T_M (°C)
R65A	60.1 ± 0.5
K68A	58.7 ± 0.6
Q72A	62.8 ± 0.4
V76A	58.3 ± 1.4
R145A (control)	61.0 ± 0.9
E154A	61.5 ± 0.3
Q155A	61.0 ± 0.6

Supplementary Table 7 Thermal stability measurements of wild-type and mutant HLA-A*11:01-GTS1 complexes.